Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.

Simón Serrano S, Grönberg A, Longato L, Rombouts K, Kuo J, Gregory M, Moss S, Elmér E, Mazza G, Gallay P, Pinzani M, Hansson MJ, Massoumi R.

Cells. 2019 Nov 8;8(11). pii: E1409. doi: 10.3390/cells8111409.

2.

The adenosine monophosphate-activated protein kinase-vacuolar adenosine triphosphatase-pH axis: A key regulator of the profibrogenic phenotype of human hepatic stellate cells.

Marrone G, De Chiara F, Böttcher K, Levi A, Dhar D, Longato L, Mazza G, Zhang Z, Marrali M, Fernández-Iglesias A, Hall A, Luong TV, Viollet B, Pinzani M, Rombouts K.

Hepatology. 2018 Sep;68(3):1140-1153. doi: 10.1002/hep.30029. Epub 2018 Jul 16.

PMID:
29663481
3.

Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling.

Sato-Matsubara M, Matsubara T, Daikoku A, Okina Y, Longato L, Rombouts K, Thuy LTT, Adachi J, Tomonaga T, Ikeda K, Yoshizato K, Pinzani M, Kawada N.

J Biol Chem. 2017 Nov 17;292(46):18961-18972. doi: 10.1074/jbc.M117.793794. Epub 2017 Sep 15.

4.

Rapid production of human liver scaffolds for functional tissue engineering by high shear stress oscillation-decellularization.

Mazza G, Al-Akkad W, Telese A, Longato L, Urbani L, Robinson B, Hall A, Kong K, Frenguelli L, Marrone G, Willacy O, Shaeri M, Burns A, Malago M, Gilbertson J, Rendell N, Moore K, Hughes D, Notingher I, Jell G, Del Rio Hernandez A, De Coppi P, Rombouts K, Pinzani M.

Sci Rep. 2017 Jul 17;7(1):5534. doi: 10.1038/s41598-017-05134-1.

5.

Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro.

Longato L, Andreola F, Davies SS, Roberts JL, Fusai G, Pinzani M, Moore K, Rombouts K.

Free Radic Biol Med. 2017 Jan;102:162-173. doi: 10.1016/j.freeradbiomed.2016.11.036. Epub 2016 Nov 24.

PMID:
27890721
6.

Activation of signal transduction pathways during hepatic oncogenesis.

Chung W, Kim M, de la Monte S, Longato L, Carlson R, Slagle BL, Dong X, Wands JR.

Cancer Lett. 2016 Jan 1;370(1):1-9. doi: 10.1016/j.canlet.2015.09.016. Epub 2015 Oct 1.

7.

Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation.

Mazza G, Rombouts K, Rennie Hall A, Urbani L, Vinh Luong T, Al-Akkad W, Longato L, Brown D, Maghsoudlou P, Dhillon AP, Fuller B, Davidson B, Moore K, Dhar D, De Coppi P, Malago M, Pinzani M.

Sci Rep. 2015 Aug 7;5:13079. doi: 10.1038/srep13079.

8.

Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin.

Tong M, Longato L, Ramirez T, Zabala V, Wands JR, de la Monte SM.

Int J Exp Pathol. 2014 Feb;95(1):49-63. doi: 10.1111/iep.12052. Epub 2013 Oct 29.

9.

Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?

Longato L.

Fibrogenesis Tissue Repair. 2013 Jul 18;6(1):14. doi: 10.1186/1755-1536-6-14.

10.

Ceramide inhibitor myriocin restores insulin/insulin growth factor signaling for liver remodeling in experimental alcohol-related steatohepatitis.

Lizarazo D, Zabala V, Tong M, Longato L, de la Monte SM.

J Gastroenterol Hepatol. 2013 Oct;28(10):1660-8. doi: 10.1111/jgh.12291.

11.

Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis.

Ramirez T, Longato L, Dostalek M, Tong M, Wands JR, de la Monte SM.

Alcohol Alcohol. 2013 Jan-Feb;48(1):39-52. doi: 10.1093/alcalc/ags106. Epub 2012 Sep 20.

12.

Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease.

Longato L, Ripp K, Setshedi M, Dostalek M, Akhlaghi F, Branda M, Wands JR, de la Monte SM.

Oxid Med Cell Longev. 2012;2012:479348. doi: 10.1155/2012/479348. Epub 2012 Apr 22.

13.

Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease.

de la Monte SM, Re E, Longato L, Tong M.

J Alzheimers Dis. 2012;30 Suppl 2:S217-29. doi: 10.3233/JAD-2012-111728.

14.

High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism.

Longato L, Tong M, Wands JR, de la Monte SM.

Hepatol Res. 2012 Apr;42(4):412-27. doi: 10.1111/j.1872-034X.2011.00934.x. Epub 2011 Dec 16.

15.

Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels.

Promrat K, Longato L, Wands JR, de la Monte SM.

Hepatol Res. 2011 Aug;41(8):754-62. doi: 10.1111/j.1872-034X.2011.00815.x.

16.

Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis.

Setshedi M, Longato L, Petersen DR, Ronis M, Chen WC, Wands JR, de la Monte SM.

Alcohol Clin Exp Res. 2011 Dec;35(12):2139-51. doi: 10.1111/j.1530-0277.2011.01569.x. Epub 2011 Jul 25.

17.

Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance.

de la Monte SM, Pang M, Chaudhry R, Duan K, Longato L, Carter J, Ouh J, Wands JR.

Hepatol Res. 2011 Apr;41(4):386-98. doi: 10.1111/j.1872-034X.2011.00775.x. Epub 2011 Feb 24.

18.

Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance.

Denucci SM, Tong M, Longato L, Lawton M, Setshedi M, Carlson RI, Wands JR, de la Monte SM.

Gastroenterol Res Pract. 2010;2010. pii: 312790. doi: 10.1155/2010/312790. Epub 2010 Aug 16.

19.

Ceramide-mediated insulin resistance and impairment of cognitive-motor functions.

de la Monte SM, Tong M, Nguyen V, Setshedi M, Longato L, Wands JR.

J Alzheimers Dis. 2010;21(3):967-84. doi: 10.3233/JAD-2010-091726.

20.

Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration.

Tong M, Longato L, de la Monte SM.

BMC Endocr Disord. 2010 Mar 19;10:4. doi: 10.1186/1472-6823-10-4.

Supplemental Content

Loading ...
Support Center